[go: up one dir, main page]

MX2018014573A - Vacuna contra el virus del zika. - Google Patents

Vacuna contra el virus del zika.

Info

Publication number
MX2018014573A
MX2018014573A MX2018014573A MX2018014573A MX2018014573A MX 2018014573 A MX2018014573 A MX 2018014573A MX 2018014573 A MX2018014573 A MX 2018014573A MX 2018014573 A MX2018014573 A MX 2018014573A MX 2018014573 A MX2018014573 A MX 2018014573A
Authority
MX
Mexico
Prior art keywords
nucleic acid
polypeptides
zika virus
artificial nucleic
vaccines
Prior art date
Application number
MX2018014573A
Other languages
English (en)
Inventor
Girerd-Chambaz Yves
Petsch Benjamin
Jasny Edith
Original Assignee
Curevac Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curevac Ag filed Critical Curevac Ag
Publication of MX2018014573A publication Critical patent/MX2018014573A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se dirige a un ácido nucleico artificial y a polipéptidos adecuados para su uso en el tratamiento o profilaxis de una infección con Virus del Zika o un trastorno relacionado con dicha infección. En particular, la presente invención se refiera a una vacuna del virus del Zika. La presente invención se dirige a un ácido nucleico artificial, polipéptidos, composiciones y vacunas que comprenden al ácido nucleico artificial o los polipéptidos. La invención además se refiere a un método para tratar o prevenir un trastorno o una enfermedad, primeros y segundos usos médicos del ácido nucleico artificial, polipéptidos, composiciones y vacunas. Además, la invención se dirige a un kit, particularmente a un kit de partes, que comprenden al ácido nucleico artificial, polipéptidos, composiciones y vacunas.
MX2018014573A 2016-02-17 2018-08-15 Vacuna contra el virus del zika. MX2018014573A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2016053398 2016-02-17

Publications (1)

Publication Number Publication Date
MX2018014573A true MX2018014573A (es) 2019-09-04

Family

ID=55398295

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018009917A MX2018009917A (es) 2016-02-17 2017-02-17 Vacuna contra el virus del zika.
MX2018014573A MX2018014573A (es) 2016-02-17 2018-08-15 Vacuna contra el virus del zika.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018009917A MX2018009917A (es) 2016-02-17 2017-02-17 Vacuna contra el virus del zika.

Country Status (6)

Country Link
US (2) US11723967B2 (es)
EP (1) EP3416683A1 (es)
BR (1) BR112018016755A2 (es)
MX (2) MX2018009917A (es)
SG (2) SG10201913630YA (es)
WO (1) WO2017140905A1 (es)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
SG10201710631RA (en) 2012-03-27 2018-02-27 Curevac Ag Artificial nucleic acid molecules for improved protein or peptide expression
WO2014127917A1 (en) 2013-02-22 2014-08-28 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
AU2014310931B2 (en) 2013-08-21 2019-12-19 CureVac SE Rabies vaccine
CA2915730A1 (en) 2013-08-21 2015-02-26 Karl-Josef Kallen A combination rsv/influenza a vaccine
SG11201510746WA (en) 2013-08-21 2016-03-30 Curevac Ag Respiratory syncytial virus (rsv) vaccine
EP3590529A1 (en) 2014-03-12 2020-01-08 CureVac AG Combination of vaccination and ox40 agonists
PT3766916T (pt) 2014-06-25 2022-11-28 Acuitas Therapeutics Inc Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos
DE202015010001U1 (de) 2014-12-12 2023-07-03 CureVac SE Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
JP2018526321A (ja) 2015-04-27 2018-09-13 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 適応免疫応答を誘導するためのヌクレオシド修飾ｒｎａ
WO2016180430A1 (en) 2015-05-08 2016-11-17 Curevac Ag Method for producing rna
PT4108769T (pt) 2015-05-29 2023-10-10 Curevac Mfg Gmbh Um método para produção e purificação de rna, compreendendendo pelo menos um passo de filtração por fluxo tangencial
CN107922364B (zh) 2015-06-29 2021-12-31 爱康泰生治疗公司 用于递送核酸的脂质和脂质纳米颗粒制剂
WO2017015463A2 (en) * 2015-07-21 2017-01-26 Modernatx, Inc. Infectious disease vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
WO2017064146A1 (en) 2015-10-12 2017-04-20 Curevac Ag Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
EP3364950A4 (en) 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
PT3368507T (pt) 2015-10-28 2023-02-07 Acuitas Therapeutics Inc Novos lípidos e formulações de nanopartículas lipídicas para distribuição de ácidos nucleicos
US11413346B2 (en) 2015-11-09 2022-08-16 Curevac Ag Rotavirus vaccines
AU2016375021B2 (en) 2015-12-22 2022-02-03 CureVac SE Method for producing RNA molecule compositions
EP3394280A1 (en) 2015-12-23 2018-10-31 CureVac AG Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
WO2017140905A1 (en) 2016-02-17 2017-08-24 Curevac Ag Zika virus vaccine
BR112018017307A2 (pt) 2016-02-25 2019-01-08 Univ Pennsylvania molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus
US11920174B2 (en) 2016-03-03 2024-03-05 CureVac SE RNA analysis by total hydrolysis and quantification of released nucleosides
EP3448427A1 (en) 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
WO2017191258A1 (en) 2016-05-04 2017-11-09 Curevac Ag Influenza mrna vaccines
EP3452493B1 (en) 2016-05-04 2025-01-15 CureVac SE Nucleic acid molecules and uses thereof
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
RU2751001C2 (ru) 2016-06-09 2021-07-07 Кьюрвак Аг Гибридные носители для доставки нуклеиновых кислот
EP3468593A4 (en) * 2016-06-09 2019-12-18 Beth Israel Deaconess Medical Center, Inc. COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING A ZIKA VIRUS INFECTION
EP3497246A1 (en) * 2016-08-08 2019-06-19 The Secretary of State for Health Flavivirus diagnostic assay
KR20190095252A (ko) 2016-09-16 2019-08-14 페블 랩스 질병-전염성 모기의 생물학적 방제를 위한 파라트랜스제닉 시스템
US11279923B2 (en) 2016-11-28 2022-03-22 Curevac Ag Method for purifying RNA
WO2018102659A1 (en) * 2016-12-01 2018-06-07 The Trustees Of Columbia University In The City Of New York Serological assay for zika virus infection
WO2018104538A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rna for treatment or prophylaxis of a liver disease
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
US11524066B2 (en) 2016-12-23 2022-12-13 CureVac SE Henipavirus vaccine
WO2018115525A1 (en) 2016-12-23 2018-06-28 Curevac Ag Lassa virus vaccine
WO2018115527A2 (en) 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
EP3568155A4 (en) 2017-01-11 2020-09-23 The Trustees Of The University Of Pennsylvania RNA MODIFIED BY NUCLEOSIDE TO INDUCE AN IMMUNE RESPONSE AGAINST ZIKA VIRUS
MA47515A (fr) 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
WO2018172556A1 (en) 2017-03-24 2018-09-27 Curevac Ag Nucleic acids encoding crispr-associated proteins and uses thereof
US11357856B2 (en) 2017-04-13 2022-06-14 Acuitas Therapeutics, Inc. Lipids for delivery of active agents
EP3615054A4 (en) 2017-04-27 2021-03-24 The Trustees Of The University Of Pennsylvania NUCLEOSIDE MODIFIED MRNA-LIPID NANOPARTICLE LINE VACCINE FOR THE HEPATITIS C VIRUS
JP7297676B2 (ja) 2017-04-28 2023-06-26 アクイタス セラピューティクス インコーポレイテッド 新規なカルボニル脂質、および核酸を送達するための脂質ナノ粒子製剤
US12297489B2 (en) 2017-05-17 2025-05-13 CureVac Manufacturing GmbH Method for determining at least one quality parameter of an RNA sample
ES3013993T3 (en) 2017-07-04 2025-04-16 CureVac SE Cancer rna-vaccine
WO2019036008A1 (en) 2017-08-16 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
US11542225B2 (en) 2017-08-17 2023-01-03 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US11524932B2 (en) 2017-08-17 2022-12-13 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
WO2019036000A1 (en) 2017-08-17 2019-02-21 Acuitas Therapeutics, Inc. LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS
WO2019038332A1 (en) 2017-08-22 2019-02-28 Curevac Ag VACCINE AGAINST BUNYAVIRUS
EP3681514A4 (en) 2017-09-14 2021-07-14 ModernaTX, Inc. RNA VACZINE AGAINST ZIKA VIRUS
US11426457B2 (en) 2017-09-21 2022-08-30 Emergex Vaccines Holding Limited MHC class I associated peptides for prevention and treatment of zika virus
EP3697912A1 (en) 2017-10-19 2020-08-26 CureVac AG Novel artificial nucleic acid molecules
MY193736A (en) 2017-11-03 2022-10-27 Takeda Vaccines Inc Method for inactivating zika virus and for determining the completeness of inactivation
EP3707271A1 (en) 2017-11-08 2020-09-16 CureVac AG Rna sequence adaptation
JP7225254B2 (ja) * 2017-11-09 2023-02-20 アンスティテュ・パストゥール 非構造タンパク質を含むジカウイルスキメラポリエピトープ、及び免疫原性組成物におけるその使用
US11739348B2 (en) 2017-11-10 2023-08-29 The Research Institute At Nationwide Children's Hospital Recombinant vectors encoding Zika virus protein subunits
WO2019108976A1 (en) 2017-11-30 2019-06-06 Takeda Vaccines, Inc. Method for inactivating zika virus and related methods
WO2019115635A1 (en) 2017-12-13 2019-06-20 Curevac Ag Flavivirus vaccine
US11525158B2 (en) 2017-12-21 2022-12-13 CureVac SE Linear double stranded DNA coupled to a single support or a tag and methods for producing said linear double stranded DNA
EP3729093A1 (en) * 2017-12-21 2020-10-28 Pepperprint GmbH Ns2b as marker for zika virus infections
CN108210921A (zh) * 2017-12-29 2018-06-29 广州恩宝生物医药科技有限公司 一种寨卡病毒疫苗及其制备方法
US11690904B2 (en) * 2018-01-06 2023-07-04 Emergex Vaccines Holding Limited MHC class I associated peptides for prevention and treatment of multiple flavi virus
CN108484737B (zh) * 2018-02-09 2021-04-23 四川农业大学 坦布苏病毒非结构蛋白ns4b截短蛋白的表达方法及其产品和应用
WO2019186199A1 (en) * 2018-03-29 2019-10-03 Emergex Vaccines Holding Limited Vaccine compositions
AU2019254591B2 (en) 2018-04-17 2025-12-11 CureVac SE Novel RSV RNA molecules and compositions for vaccination
BR112020025601A8 (pt) 2018-06-28 2022-07-05 Tesla Automation GmbH Biorreator para a transcrição in vitro de rna
AU2019310347A1 (en) 2018-07-23 2021-03-04 The University Of Adelaide Zika virus vaccine
US11702453B2 (en) 2018-08-21 2023-07-18 Regents Of The University Of Michigan Materials and methods for inhibiting flavivirus infection
CA3113449A1 (en) 2018-09-21 2020-03-26 Acuitas Therapeutics, Inc. Systems and methods for manufacturing lipid nanoparticles and liposomes
TW202039534A (zh) 2018-12-14 2020-11-01 美商美國禮來大藥廠 KRAS變體mRNA分子
CA3122645A1 (en) 2018-12-21 2020-06-25 Curevac Ag Methods for rna analysis
US12070495B2 (en) 2019-03-15 2024-08-27 Modernatx, Inc. HIV RNA vaccines
US20220168412A1 (en) * 2019-04-10 2022-06-02 Katholieke Universiteit Leuven Chimeric Zika-Japanese Encephalitis Virus
JP2023507465A (ja) 2019-12-20 2023-02-22 キュアバック エスイー 核酸を送達するための脂質ナノ粒子
US12194089B2 (en) 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
US12521429B2 (en) 2020-02-05 2026-01-13 New York Blood Center, Inc. Zika virus immunogenic compositions
JP7759333B2 (ja) * 2020-03-03 2025-10-23 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ ジカウイルスポリペプチド
CN111514286B (zh) * 2020-04-01 2022-03-08 中国科学院过程工程研究所 一种寨卡病毒e蛋白结合疫苗及其制备方法
WO2021262659A1 (en) * 2020-06-22 2021-12-30 University Of Connecticut Flavivirus signal peptides, vaccine constructs, and methods therefor
WO2022016070A1 (en) 2020-07-16 2022-01-20 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
KR102557824B1 (ko) * 2020-08-18 2023-07-20 주식회사 바이오앱 식물 발현 재조합 지카바이러스 외피단백질을 포함하는 백신 조성물 및 이의 제조방법
US11918643B2 (en) 2020-12-22 2024-03-05 CureVac SE RNA vaccine against SARS-CoV-2 variants
CU24751B1 (es) * 2021-07-28 2025-06-11 Ct Ingenieria Genetica Biotecnologia Antígeno recombinante para la inducción de respuesta inmune contra el virus zika
WO2023018817A1 (en) 2021-08-11 2023-02-16 Sanofi Pasteur Inc. Truncated influenza neuraminidase and methods of using the same
WO2023031392A2 (en) 2021-09-03 2023-03-09 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine
US20240398940A1 (en) 2021-09-03 2024-12-05 CureVac SE Novel lipid nanoparticles for delivery of nucleic acids
WO2023114943A2 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
US12186389B2 (en) 2022-10-28 2025-01-07 Glaxosmithkline Biologicals Sa Nucleic acid base vaccine against emerging SARS-CoV-2 variants
AU2024233180A1 (en) 2023-03-08 2025-09-25 CureVac SE Novel lipid nanoparticle formulations for delivery of nucleic acids
CN116855514A (zh) * 2023-07-14 2023-10-10 中国科学院微生物研究所 编码寨卡病毒抗原肽的mRNA、基于其的mRNA疫苗及其制备方法
WO2025043010A1 (en) * 2023-08-23 2025-02-27 Vyro Bio Inc. Nucleic acid compositions for the generation of a zika virus-like particle
CN120241984A (zh) * 2025-06-04 2025-07-04 中国食品药品检定研究院 一种双组份寨卡mRNA疫苗及其用途

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1604688B1 (de) 2001-06-05 2010-02-03 CureVac GmbH Stabilisierte Tumorantigen-mRNA mit erhöhtem G/C-Gehalt
DE10162480A1 (de) 2001-12-19 2003-08-07 Ingmar Hoerr Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
DE10229872A1 (de) 2002-07-03 2004-01-29 Curevac Gmbh Immunstimulation durch chemisch modifizierte RNA
DE10335833A1 (de) 2003-08-05 2005-03-03 Curevac Gmbh Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie
DE102004042546A1 (de) 2004-09-02 2006-03-09 Curevac Gmbh Kombinationstherapie zur Immunstimulation
DE102005023170A1 (de) 2005-05-19 2006-11-23 Curevac Gmbh Optimierte Formulierung für mRNA
DE102006035618A1 (de) 2006-07-31 2008-02-07 Curevac Gmbh Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
DE102006061015A1 (de) 2006-12-22 2008-06-26 Curevac Gmbh Verfahren zur Reinigung von RNA im präparativen Maßstab mittels HPLC
DE102007001370A1 (de) 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
US9226959B2 (en) 2008-01-31 2016-01-05 Curevac Ag Nucleic acids comprising formula (NuGlXmGnNv)a and derivatives thereof as immunostimulating agent/adjuvant
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
US8691961B1 (en) * 2009-11-09 2014-04-08 Integral Molecular, Inc. Flavivirus reporter virus and methods of making and using the same
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
EP2955230A1 (en) 2010-07-30 2015-12-16 CureVac AG Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
WO2012019630A1 (en) * 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
EP2623121A1 (en) 2012-01-31 2013-08-07 Bayer Innovation GmbH Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120500A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013120498A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
ES2660129T3 (es) * 2012-03-27 2018-03-20 Curevac Ag Moléculas de ácido nucleico artificiales que comprenden un 5'UTR-TOP
RU2651498C2 (ru) 2012-03-27 2018-04-19 Кьюрвак Аг Молекулы искусственной нуклеиновой кислоты
SG10201710631RA (en) 2012-03-27 2018-02-27 Curevac Ag Artificial nucleic acid molecules for improved protein or peptide expression
EP3498267A1 (en) 2012-05-25 2019-06-19 CureVac AG Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
WO2014127917A1 (en) 2013-02-22 2014-08-28 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
AU2014310931B2 (en) 2013-08-21 2019-12-19 CureVac SE Rabies vaccine
ES2759910T3 (es) 2013-08-21 2020-05-12 Curevac Ag Composición y vacuna para el tratamiento del cáncer de pulmón
SG11201510747RA (en) 2013-08-21 2016-03-30 Curevac Ag Method for increasing expression of rna-encoded proteins
SG11201510746WA (en) 2013-08-21 2016-03-30 Curevac Ag Respiratory syncytial virus (rsv) vaccine
SG10201801433XA (en) 2013-08-21 2018-04-27 Curevac Ag Composition and vaccine for treating prostate cancer
CA2915730A1 (en) 2013-08-21 2015-02-26 Karl-Josef Kallen A combination rsv/influenza a vaccine
CA2925021C (en) 2013-11-01 2025-05-06 Curevac Ag MODIFIED MESSENGER RIBONUCLE ACID (MRNA) WITH REDUCED IMMUNOSTIMULATING PROPERTIES
JP6584414B2 (ja) 2013-12-30 2019-10-02 キュアバック アーゲー 人工核酸分子
SG10201805660WA (en) 2013-12-30 2018-08-30 Curevac Ag Methods for rna analysis
AU2014375402B2 (en) 2013-12-30 2020-10-01 CureVac SE Artificial nucleic acid molecules
EP3590529A1 (en) 2014-03-12 2020-01-08 CureVac AG Combination of vaccination and ox40 agonists
EP3129050A2 (en) 2014-04-01 2017-02-15 CureVac AG Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
PT3155129T (pt) 2014-06-10 2019-05-16 Curevac Ag Método para potenciar a produção de arn
DE202015010001U1 (de) 2014-12-12 2023-07-03 CureVac SE Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
EP3233113A1 (en) 2014-12-16 2017-10-25 CureVac AG Ebolavirus and marburgvirus vaccines
WO2016107877A1 (en) 2014-12-30 2016-07-07 Curevac Ag Artificial nucleic acid molecules
EP3283059B1 (en) 2015-04-13 2024-01-03 CureVac Manufacturing GmbH Method for producing rna compositions
CN107567497A (zh) 2015-04-17 2018-01-09 库瑞瓦格股份公司 Rna的冻干
SG10201907164SA (en) 2015-04-22 2019-09-27 Curevac Ag Rna containing composition for treatment of tumor diseases
CN107889503A (zh) 2015-04-30 2018-04-06 库瑞瓦格股份公司 固定化的聚(n)聚合酶
WO2016174227A1 (en) 2015-04-30 2016-11-03 Curevac Ag Method for in vitro transcription using an immobilized restriction enzyme
WO2016180430A1 (en) 2015-05-08 2016-11-17 Curevac Ag Method for producing rna
KR20180004820A (ko) 2015-05-15 2018-01-12 큐어백 아게 적어도 하나의 mRNA 구성의 투여를 포함하는 신규 프라임-부스트 요법
CN107530448A (zh) 2015-05-20 2018-01-02 库瑞瓦格股份公司 包含长链rna的干粉组合物
EP3916091A3 (en) 2015-05-20 2022-03-30 CureVac AG Dry powder composition comprising long-chain rna
EP3303575B1 (en) 2015-05-29 2022-03-16 CureVac AG Method for adding cap structures to rna using immobilized enzymes
PT4108769T (pt) 2015-05-29 2023-10-10 Curevac Mfg Gmbh Um método para produção e purificação de rna, compreendendendo pelo menos um passo de filtração por fluxo tangencial
EP3310384A1 (en) 2015-06-17 2018-04-25 CureVac AG Vaccine composition
US10799575B2 (en) 2015-06-25 2020-10-13 Technovax, Inc. Flavivirus and alphavirus virus-like particles (VLPS)
WO2017001058A1 (en) 2015-07-01 2017-01-05 Curevac Ag Method for analysis of an rna molecule
WO2017009376A1 (en) 2015-07-13 2017-01-19 Curevac Ag Method of producing rna from circular dna and corresponding template dna
WO2017015463A2 (en) 2015-07-21 2017-01-26 Modernatx, Inc. Infectious disease vaccines
WO2017021546A1 (en) 2015-08-05 2017-02-09 Curevac Ag Epidermal mrna vaccine
EP3699288A1 (en) 2015-08-07 2020-08-26 CureVac AG Process for the in vivo production of rna in a host cell
CN116064623A (zh) 2015-08-10 2023-05-05 库瑞瓦格制造业有限公司 增加环状dna分子复制的方法
SG10201913629VA (en) 2015-08-28 2020-03-30 Curevac Ag Artificial nucleic acid molecules
WO2017064146A1 (en) 2015-10-12 2017-04-20 Curevac Ag Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
EP3364950A4 (en) * 2015-10-22 2019-10-23 ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
US11413346B2 (en) 2015-11-09 2022-08-16 Curevac Ag Rotavirus vaccines
US20180312545A1 (en) 2015-11-09 2018-11-01 Curevac Ag Optimized nucleic acid molecules
EP3394237A1 (en) 2015-12-21 2018-10-31 CureVac AG Inlay for a culture plate and corresponding method for preparing a culture plate system with such inlay
AU2016375021B2 (en) 2015-12-22 2022-02-03 CureVac SE Method for producing RNA molecule compositions
EP3394280A1 (en) 2015-12-23 2018-10-31 CureVac AG Method of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
US20210180106A1 (en) 2016-02-12 2021-06-17 Curevac Ag Method for analyzing rna
WO2017140345A1 (en) 2016-02-15 2017-08-24 Curevac Ag Method for analyzing by-products of rna in vitro transcription
WO2017140905A1 (en) 2016-02-17 2017-08-24 Curevac Ag Zika virus vaccine
US11920174B2 (en) 2016-03-03 2024-03-05 CureVac SE RNA analysis by total hydrolysis and quantification of released nucleosides
WO2017161151A1 (en) * 2016-03-16 2017-09-21 Novavax, Inc. Vaccine compositions containing modified zika virus antigens
EP3433361A1 (en) 2016-03-24 2019-01-30 CureVac AG Immobilized inorganic pyrophosphatase (ppase)
US20190343942A1 (en) 2016-04-22 2019-11-14 Curevac Ag Rna encoding a tumor antigen
EP3448427A1 (en) 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
US20180126003A1 (en) 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
WO2017191258A1 (en) 2016-05-04 2017-11-09 Curevac Ag Influenza mrna vaccines
EP3452493B1 (en) 2016-05-04 2025-01-15 CureVac SE Nucleic acid molecules and uses thereof
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
EP3464619A1 (en) 2016-05-25 2019-04-10 CureVac AG Novel biomarkers
EP3468612A1 (en) 2016-06-09 2019-04-17 CureVac AG Hybrid carriers for nucleic acid cargo
US20190336611A1 (en) 2016-06-09 2019-11-07 Curevac Ag Hybrid carriers for nucleic acid cargo
EP3468609A1 (en) 2016-06-09 2019-04-17 CureVac AG Cationic carriers for nucleic acid delivery
RU2751001C2 (ru) 2016-06-09 2021-07-07 Кьюрвак Аг Гибридные носители для доставки нуклеиновых кислот
JP2019526556A (ja) 2016-08-19 2019-09-19 キュアバック アーゲー 癌治療用ｒｎａ
WO2018052549A1 (en) * 2016-09-19 2018-03-22 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Zika virus vaccines
IL301800B2 (en) 2016-10-26 2025-05-01 Curevac Ag mRNA vaccines with lipid nanoparticles
US11279923B2 (en) 2016-11-28 2022-03-22 Curevac Ag Method for purifying RNA
WO2018104540A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rnas for wound healing
WO2018104538A1 (en) 2016-12-08 2018-06-14 Curevac Ag Rna for treatment or prophylaxis of a liver disease
US11524066B2 (en) 2016-12-23 2022-12-13 CureVac SE Henipavirus vaccine
WO2018115527A2 (en) 2016-12-23 2018-06-28 Curevac Ag Mers coronavirus vaccine
WO2018115525A1 (en) 2016-12-23 2018-06-28 Curevac Ag Lassa virus vaccine
EP3568155A4 (en) 2017-01-11 2020-09-23 The Trustees Of The University Of Pennsylvania RNA MODIFIED BY NUCLEOSIDE TO INDUCE AN IMMUNE RESPONSE AGAINST ZIKA VIRUS
WO2018167320A1 (en) 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
WO2018172556A1 (en) 2017-03-24 2018-09-27 Curevac Ag Nucleic acids encoding crispr-associated proteins and uses thereof
ES3013993T3 (en) 2017-07-04 2025-04-16 CureVac SE Cancer rna-vaccine
WO2019038332A1 (en) 2017-08-22 2019-02-28 Curevac Ag VACCINE AGAINST BUNYAVIRUS
WO2019115635A1 (en) 2017-12-13 2019-06-20 Curevac Ag Flavivirus vaccine
US11525158B2 (en) 2017-12-21 2022-12-13 CureVac SE Linear double stranded DNA coupled to a single support or a tag and methods for producing said linear double stranded DNA
WO2019193183A2 (en) 2018-04-05 2019-10-10 Curevac Ag Novel yellow fever nucleic acid molecules for vaccination
AU2019254591B2 (en) 2018-04-17 2025-12-11 CureVac SE Novel RSV RNA molecules and compositions for vaccination
BR112020025601A8 (pt) 2018-06-28 2022-07-05 Tesla Automation GmbH Biorreator para a transcrição in vitro de rna
CN113453707A (zh) 2018-12-21 2021-09-28 库瑞瓦格股份公司 用于疟疾疫苗的rna
CA3122645A1 (en) 2018-12-21 2020-06-25 Curevac Ag Methods for rna analysis
AU2021206307A1 (en) 2020-01-11 2022-09-08 Sivec Biotechnologies Llc A microbial system for production and delivery of eukaryote-translatable mRNA to eukarya
US11241493B2 (en) 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
WO2021211343A1 (en) 2020-04-13 2021-10-21 Modernatx, Inc. Zika virus mrna vaccines

Also Published As

Publication number Publication date
SG10201913630YA (en) 2020-03-30
US20210205434A1 (en) 2021-07-08
US12496335B2 (en) 2025-12-16
US11723967B2 (en) 2023-08-15
BR112018016755A2 (en) 2018-12-26
MX2018009917A (es) 2019-08-14
WO2017140905A1 (en) 2017-08-24
SG11201806340YA (en) 2018-09-27
EP3416683A1 (en) 2018-12-26
US20240024453A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
MX2018014573A (es) Vacuna contra el virus del zika.
EP4477662A3 (en) Nucleic acid molecules and uses thereof
CL2019003264A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)
BR112017017949A2 (pt) regimes de iniciação-reforço envolvendo administração de pelo menos um constructo de mrna
CL2017002230A1 (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsida del vhb.
UY37581A (es) Compuestos para el tratamiento de la infección por virus de la hepatitis b
CL2018001159A1 (es) Vacuna para adenovirus aviar (divisional de solicitud n° 358-2016)
MX2018007198A (es) Antigenos del virus de la inmunodeficiencia humana, vectores, composiciones y metodos de uso de estos.
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
MX2019002678A (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv.
PE20151588A1 (es) Vacuna contra el virus del dengue
MX2020004543A (es) Vacunas contra el zika, composiciones inmunogenicas y metodos que las utilizan.
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
CO2018010874A2 (es) Vacuna de virus de zika atenuado vivo
CL2020001901A1 (es) Vacunas contra virus de la gripe y usos de las mismas.
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
MX2017003117A (es) Particula tipo virus de flavivirus.
BR112018015893A2 (pt) vacinas de câncer e métodos de tratamento usando as mesmas
MX2017005687A (es) Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia.
MX2023012390A (es) Vacunacion con particulas de replicon y adyuvante oleoso.
UY39464A (es) Composiciones y métodos para la prevención y/o tratamiento de la covid-19
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
MX2018016306A (es) Virus de enteritis de pato y usos del mismo.
MX381252B (es) Virus de la enteritis del pato y usos del mismo.